Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In ...

Retrieved on: 2024-07-24 07:17:42

Tags for this article:

Click the tags to see associated articles and topics

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In .... View article details on hiswai:

Excerpt

Sanofi SA (NASDAQ:) /AstraZeneca Plc's (NASDAQ:AZN) Beyfortus (nirsevimab) received FDA approval in June 2023 for the prevention of respiratory ...

Article found on: quantisnow.com